Tresiba Vs. Lantus: Novo Nordisk Scores A Win In Second Head-To-Head
This article was originally published in The Pink Sheet Daily
Novo revealed top-line results from SWITCH 1, showing Tresiba was superior to Lantus on a secondary endpoint of severe hypoglycemia in the maintenance period in type 1 diabetics, a positive after Tresiba failed to show superiority on the endpoint in another trial, SWITCH 2, in type 2 diabetes.
You may also be interested in...
Keeping Track: Submissions Galore, Blincyto Supplemental Approval, And Priority Review For Opdivo/Yervoy Combo
The latest drug development news and highlights from our US FDA Performance Tracker.
Cardiovascular outcomes trials headlined the recent ADA meeting. Scrip spoke with executives from Novo, Boehringer, AstraZeneca and Merck at the conference about the value of CV data and real world evidence in an era when managing diabetes is about much more than lowering blood glucose.
The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.